uniQure, a gene therapy company advancing transformative therapies for patients with severe medical needs, completed the acquisition of Corlieve Therapeutics, a biotechnology company, for $242m. Corlieve’s lead program, now designated as AMT-260, employs miRNA silencing technology to suppress aberrantly expressed kainite receptors in the hippocampus of patients with temporal lobe epilepsy (TLE). TLE represents a large unmet clinical need affecting approximately 1.3m people in the U.S. and Europe alone, of which approximately 800k patients are unable to adequately control acute seizures with currently approved anti-epileptic therapies. The acquisition was announced in June 2021 during the Company’s virtual Research & Development Day.